Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

NCT03898180 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

505

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Lenvatinib
DRUG: Placebo for lenvatinib

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]